CPIX
Cumberland Pharmaceuticals Inc.
$2.78
-$0.21(-7.02%)
51
Overall
60
Value
40
Tech
55
Quality
Market Cap
$47.12M
Volume
117.34K
52W Range
$1.04 - $7.25
Target Price
$8.50
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $33.5M | $33.0M | $41.2M | $40.7M | $34.4M | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | ||
| Total Revenue | $33.0M | $32.5M | $41.2M | $40.7M | $34.4M | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-5.0M | $-6.0M | $-7.4M | $-6.0M | $7.4M | $8.7M | $8.8M | $9.1M | $6.1M | $6.6M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $28.6M | $27.1M | $33.8M | $33.4M | $27.0M | $28.8M | $27.2M | $32.9M | $33.5M | $31.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $27.4M | $28.5M | $37.9M | $43.6M | $36.3M | $35.2M | $34.9M | $38.6M | $42.7M | $37.5M | ||
| Research & Development | $3.8M | $3.2M | $3.9M | $7.6M | $6.9M | $5.8M | $5.7M | $6.7M | $5.8M | $4.8M | ||
| Research Expense | $3.8M | $3.2M | $3.9M | $7.6M | $6.9M | $5.8M | $5.7M | $6.7M | $5.8M | $4.8M | ||
| Selling, General & Administrative | $21.6M | $23.1M | $31.5M | $30.4M | $25.3M | $25.0M | $24.8M | $26.2M | $28.8M | $27.9M | ||
| Selling & Marketing Expenses | $14.0M | $14.6M | $21.5M | $20.3M | $15.3M | $14.8M | $15.0M | $16.7M | $18.5M | $17.0M | ||
| General & Administrative Expenses | $7.6M | $8.6M | $10.0M | $10.2M | $10.0M | $10.2M | $9.8M | $9.6M | $10.3M | $10.9M | ||
| Promotion & Advertising | $-2.6M | $-2.6M | $-2.6M | $-2.2M | $2.6M | $2.4M | $1.9M | $2.9M | $2.9M | $3.0M | ||
| Salaries & Wages | -- | -- | -- | $2.9M | -- | -- | -- | -- | $400.0K | $300.0K | ||
| Depreciation & Amortization | $2.0M | $2.2M | $2.4M | $2.8M | $4.1M | $4.4M | $4.4M | $5.1M | $8.1M | $4.7M | ||
| Depreciation & Amortization | $2.0M | $2.2M | $2.4M | $2.8M | $4.1M | $4.4M | $4.4M | $5.1M | $8.1M | $4.7M | ||
| Amortization | $2.0M | $2.2M | $2.4M | $2.8M | $4.1M | $4.4M | $4.4M | $5.1M | $8.1M | $4.7M | ||
| Securities Amortization | -- | -- | -- | -- | -- | $1.8M | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | $-621.1K | $-618.8K | $613.6K | $1.2M | $1.2M | $1.2M | $49.1M | $44.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $1.1M | $-1.4M | $-4.1M | $-10.3M | $-9.3M | $-6.4M | $-7.7M | $-5.7M | $-9.6M | $-6.4M | ||
| EBITDA | $3.6M | $1.3M | $2.7M | $-7.5M | $-4.6M | $-1.6M | $-857.8K | $332.9K | $168.8K | $210.7K | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $73.9K | $106.4K | $3.8M | $195.8K | $246.2K | $263.6K | $98.0K | $586.0K | $667.9K | $605.5K | ||
| Interest Income Operating | $622.5K | $852.1K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | $321.5K | $204.7K | $671.8K | $2.1M | $243.4K | $75.3K | $26.1K | $98.4K | $286.9K | $334.4K | ||
| Net Non-Operating Interest Income/Expense | $247.7K | $98.3K | $-3.1M | $1.9M | $-2.8K | $-188.3K | $-72.0K | $-487.6K | $-381.0K | $-271.1K | ||
| Gain on Sale of Securities | -- | -- | -- | $1.6M | $1.5M | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $5.3M | $2.7M | $-1.1M | $-1.6M | $1.1M | $440.1K | $-2.2M | $611.3K | $-2.8M | $-1.5M | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | $2.2M | -- | $2.8M | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $5.4M | $5.7M | -- | -- | ||
| Special Income Charges | -- | -- | $-3.7M | -- | -- | -- | $-5.4M | $-5.7M | $475.0K | -- | ||
| Impairment of Capital Assets | -- | -- | $3.7M | -- | -- | -- | -- | -- | $3.3M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $1.3M | $-1.2M | $-62.1K | $-10.6M | $-9.0M | $-6.3M | $-5.5M | $-5.0M | $-5.6M | $-5.9M | ||
| Pre-Tax Income | $1.2M | $-1.3M | $-3.9M | $-10.8M | $-9.3M | $-6.6M | $-5.6M | $-5.6M | $-6.3M | $-6.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $575.8K | $-330.9K | $4.2M | $16.6K | $9.1M | $55.9K | $34.9K | $68.8K | $45.8K | $-22.7K | ||
| NET INCOME | ||||||||||||
| Net Income | $-3.9M | $-3.6M | $-10.2M | $-8.3M | $-3.5M | $-3.3M | $-3.5M | $-5.6M | $-6.3M | $-6.5M | ||
| Net Income (Continuing Operations) | $-3.9M | $-3.6M | $-10.2M | $-8.3M | $-3.5M | $-3.3M | $-3.5M | $-5.7M | $-6.3M | $-6.4M | ||
| Net Income (Discontinued Operations) | $-3.9M | $-3.6M | $-10.2M | $-8.3M | $-3.5M | $-3.3M | $-3.5M | $-5.6M | $-6.3M | $-6.5M | ||
| Net Income (Common Stockholders) | $-3.9M | $-3.6M | $-10.2M | $-8.3M | $-13.7M | $-3.3M | $-3.5M | $-5.6M | $-6.3M | $-6.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-49.0M | -- | -- | $-7.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $22.5M | $22.5M | $30.5M | $37.6M | $43.7M | $43.8M | $43.7M | $47.7M | $48.8M | $44.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $16.7M | $16.2M | $15.9M | $15.6M | $15.4M | $15.2M | $14.9M | $14.6M | $14.3M | $14.1M | ||
| Average Shares Outstanding (Diluted) | $17.1M | $16.2M | $15.9M | $15.6M | $15.4M | $15.2M | $14.9M | $14.6M | $14.3M | $14.1M | ||
| Shares Outstanding | $16.3M | $16.0M | $15.7M | $15.4M | $15.2M | $14.9M | $14.8M | $14.4M | $14.2M | $14.0M | ||
| Basic EPS | $0.04 | $-0.06 | $-0.50 | $-0.45 | $-0.23 | $-0.44 | $-0.48 | $-0.76 | $-0.44 | $-0.46 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.23 | $-0.65 | $-0.61 | $-0.76 | $-0.44 | $-0.46 | ||
| Diluted EPS | $0.04 | $-0.06 | $-0.50 | $-0.45 | $-0.23 | $-0.44 | $-0.48 | $-0.76 | $-0.44 | $-0.46 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-0.23 | $-0.65 | $-0.61 | $-0.76 | $-0.44 | $-0.46 | ||
| OTHER METRICS | ||||||||||||
| Acquired In Process Rn D Income | -- | $852.1K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | $0.21 | $0.13 | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | $0.21 | $0.13 | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | $862.2K | -- | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | $862.2K | -- | -- | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | $1.0M | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | $1.1M | -- | $1.5M | -- | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | $5.7M | $3.2M | $2.0M | -- | -- | -- | ||
| Insurance And Claims | -- | -- | -- | -- | -- | -- | -- | $-611.3K | $-346.8K | $-237.1K | ||
| Minority Interests | $60.2K | $59.3K | $71.2K | $75.7K | $208.8K | $79.5K | $95.2K | $79.8K | $51.4K | $-36.1K | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | $5.7M | $3.2M | $2.0M | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | -- | -- | -- | -- | -- | $-475.0K | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | $5.7M | $3.2M | $2.0M | -- | -- | -- | ||
| Other Gand A | $7.6M | $8.6M | $10.0M | $10.2M | $10.0M | $10.2M | $9.8M | $9.6M | $10.3M | $10.9M | ||
| Other Taxes | -- | -- | -- | -- | $3.5M | -- | -- | -- | -- | -- | ||
| Other Write Down | -- | $2.5M | -- | -- | -- | $440.1K | -- | -- | -- | -- | ||
| Other Write Off | $5.3M | -- | -- | -- | $3.5M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $7.6M | $8.6M | $10.0M | $10.2M | $-688.0K | $-680.6K | -- | -- | -- | -- | ||
| Selling Expense | $14.0M | $14.6M | $21.5M | $20.3M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $5.4M | $5.7M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CPIX | $2.78 | -7.0% | 117.34K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cumberland Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW